Keeping the faith, Eisai and Biogen kick off new Phase III Alzheimer's study

22 March 2019

Just a day after development partner Biogen (Nasdaq: BIIB) revealed the Phase III failure of aducanumab, Japan’s Eisai (TYO: 4523) has announced the start of late stage testing for another runner in the firms’ stable of Alzheimer’s candidates, BAN2401.

Eisai says the global Clarity AD study will go ahead as planned, renewing faith in the potential of the collaboration, and restoring hope to millions of people affected by Alzheimer’s worldwide.

The companies have been working together to develop monoclonal antibodies to treat neurological disorders since 2014, and agreed to expand the collaboration in 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK